Chinese biotech firm WuXi AppTec to invest over $30m in CANbridge

Chinese biotech firm WuXi AppTec to invest over $30m in CANbridge

Photo: WuXi AppTec.

WuXi AppTec is planning to invest over $30 million in Beijing-based biopharmaceutical firm CANbridge Pharmaceuticals, as the mainland leading biotech firm ramps up efforts to up stakes in China’s orphan disease treatment market.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter